Novel developments in angiogenesis cancer therapy

por Hirte, H.W.
Publicado 2009

Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour.

por Clark, D. A., Hirte, H. W., Buick, R. N.
Publicado 1988

Optimal chemotherapy treatment for women with recurrent ovarian cancer

por Fung-Kee-Fung, M., Oliver, T., Elit, L., Oza, A., Hirte, H.W., Bryson, P.
Publicado 2007

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

por Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A
Publicado 2011

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

por Chen, E X, Hotte, S, Hirte, H, Siu, L L, Lyons, J, Squires, M, Lovell, S, Turner, S, McIntosh, L, Seymour, L
Publicado 2014

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado 2017

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado 2017

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

por Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Publicado 2011

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

por Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L
Publicado 2006

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

por Lee, C K, Simes, R J, Brown, C, Lord, S, Wagner, U, Plante, M, Vergote, I, Pisano, C, Parma, G, Burges, A, Bourgeois, H, Högberg, T, Bentley, J, Angleitner-Boubenizek, L, Ferrero, A, Richter, B, Hirte, H, Gebski, V, Pfisterer, J, Pujade-Lauraine, E, Friedlander, M
Publicado 2011

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

por Ledermann, J.A., Embleton-Thirsk, A.C., Perren, T.J., Jayson, G.C., Rustin, G.J.S., Kaye, S.B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A.M., Kaplan, R.S., Parmar, M.K.B.
Publicado 2021

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

por Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Publicado 2013